ADARx Pharmaceuticals, Inc. (ADRX)
| Market Cap | 1.98B |
| Revenue (ttm) | 6.13M |
| Net Income | -87.87M |
| EPS | -7.74 |
| Shares Out | 112.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 283,370 |
| Open | 17.75 |
| Previous Close | 17.83 |
| Day's Range | 17.50 - 18.33 |
| 52-Week Range | 16.64 - 23.21 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 15, 2026 |
About ADRX
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention wit... [Read more]
Financial Performance
Financial StatementsNews
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering
Opening Day: Amaero, Bamboo Insurance postpone IPOs
Amaero and Bamboo Insurance announced that both have postponed their planned IPOs, citing adverse market conditions. LATEST IPOS AND DIRECT LISTINGS: ADARx Pharmaceuticals (ADRX) opened on September 2...
ADARx Pharmaceuticals opens at $22.10, IPO priced at $17 per share
ADARx Pharmaceuticals (ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, priced its upsized initial public offering of 26.25M shares of common stock at ...
ADARx Pharmaceuticals indicated to open at $28, IPO priced at $17
ADARx Pharmaceuticals (ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, priced its upsized initial public offering of 26.25M shares of common stock at ...
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADARx Pharmaceuticals said on Thursday it had raised $446.3 million in an upsized US initial public offering, reflecting growing investor appetite for biotech listings.
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricin...
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADARx Pharmaceuticals is seeking a valuation of up to $1.74 billion in its U.S. initial public offering, the company said on Monday, as investor appetite for biotech listings strengthens.
ADARx Pharmaceuticals IPO Registration Document (S-1)
ADARx Pharmaceuticals has filed to go public with an IPO on the NASDAQ
siRNA biotech ADARx Pharmaceuticals files for a $100 million IPO
ADARx Pharmaceuticals, a Phase 3 biotech developing siRNA therapies for various diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.